As new gene therapy product development becomes patient targeted and complex, more products are being delivered by injection than orally. Development of parenteral dosage forms is more difficult than oral formulations. Chemical and physical stability are key considerations, viscosity is critical, and sterility is essential.
Ascendia’s team of scientists have decades of combined experience in sterile supplies for clinical trials, making them expert at solving the most difficult formulation challenges. In short, we consistently make the challenge task in biological delivery possible.